White Paper
Ten Most Common Reasons for FDA 483 Inspectional Observations in Pharmaceutical Environments
Loading Content
About this Document
The U.S. Food and Drug Administration (FDA) has released data on the most common observations it makes during inspections of pharmaceutical facilities. The top ten deficiencies are explored in this insightful white paper.
PDF
— 0.35MB
